NTEC - Intec Pharma Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
7.74
+0.39 (+5.31%)
As of 1:40PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close7.35
Open7.35
Bid7.71 x 1400
Ask7.75 x 1300
Day's Range7.35 - 7.84
52 Week Range3.55 - 8.08
Volume460,653
Avg. Volume229,961
Market Cap257.169M
Beta (3Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-1.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.70
Trade prices are not sourced from all markets
  • PR Newswire4 days ago

    Intec Pharma to Continue Development Collaboration to Next Phase

    JERUSALEM, Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the Accordion Pill™ developed for a proprietary Novartis compound is continuing into a clinical PK study under the previously announced Feasibility and Option agreement with Novartis Pharmaceuticals. Following achievement of the required in-vitro specifications, the companies are continuing the program into a clinical PK study during the first half of 2019.  The details of the therapeutic area or specific compound were not released.

  • ACCESSWIRE7 days ago

    Today's Research Reports on Trending Tickers: Oragenics and Intec Pharma

    NEW YORK, NY / ACCESSWIRE / December 3, 2018 / There was no news to explain the new high that Intec Pharma hit on Friday but Oragenics surged over 30% after announcing the publication of a research paper last week. Oragenics, Inc. shares closed up 33.66% on Friday with around 24.7 million shares traded. It was early last week that the company announced the publication of a research paper called "Blueprints for the rational design of therapeutic mutacin 1140 variants." The study focused on structure-activity relationships of the lantibiotic Mutacin 1140 (MU1140) that expand the “drugability” of the MU1140 pipeline.

  • GlobeNewswire19 days ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • PR Newswirelast month

    Intec Pharma Reports Third Quarter 2018 Financial Results and Corporate Update

    Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the ...

  • Reuterslast month

    Israel's Intec Pharma eyes revenue from Parkinson's drug in 2019

    Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the programme sometime in 2019. Intec recently completed enrolling 462 patients for a Phase III trial for the pill that opens up like an accordion, with the levodopa drug remaining in the stomach for 8-12 hours, requiring fewer doses a day. "I hope next year we will be able to monetize value out of the Parkinson's programme, whether that is the sale of the company, sale of the programme or a licence partnership," said Meckler, who took over in July 2017.

  • PR Newswirelast month

    Intec Pharma to Participate in Upcoming November Investment Conferences

    JERUSALEM , Nov. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

  • Benzingalast month

    A Complete List Of NYSE And NASDAQ-Listed Cannabis Companies

    As the cannabis industry keeps pushing forward, more companies are moving to list their stock on a major U.S. exchange like the NYSE or NASDAQ. On Friday, Canadian medical marijuana producer Aphria Inc ...

  • PR Newswire2 months ago

    Intec Pharma Completes Enrollment of Pivotal Phase 3 Clinical Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients

    "We are delighted to achieve this important milestone as it leads us one step closer to potentially bringing a new and much-needed baseline levodopa treatment to advanced PD patients," stated R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Intec Pharma. "The complications associated with advanced PD have a substantial impact on healthcare costs and quality-of-life.

  • PR Newswire2 months ago

    Intec Pharma to Present Multiple Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM , Sept. 25, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that three posters in support of the Company's Phase 3 clinical ...

  • PR Newswire3 months ago

    Intec Pharma to Participate at Upcoming Investment Conferences

    JERUSALEM , Sept. 20, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...

  • PR Newswire4 months ago

    Intec Pharma Reports Second Quarter 2018 Financial Results and Corporate Update

    Enrolled more than 95% of patients in pivotal Phase 3 ACCORDANCE trial and more than 85% of eligible patients entered the open label extension study JERUSALEM , Aug. 15, 2018 /PRNewswire/ --   Intec Pharma ...

  • Investopedia5 months ago

    5 Favorite Biotech Bets

    Given their dependence on the success or failure of their drug candidates, biotechnology stocks are generally high-risk propositions. Over the past couple of decades our most profitable sector has been biotech stocks. Of course, the key to almost any stock move is news.

  • PR Newswire5 months ago

    Intec Pharma Appoints William Bradley Hayes to Board of Directors

    Intec Pharma Ltd. (NTEC) (NTEC.TA) ("Intec" or "the Company") today announces the appointment of William Bradley Hayes (Brad) to the Company's Board of Directors.  Mr. Hayes was formerly Executive Vice President, Chief Financial Officer and Treasurer of Laboratory Corporation of America Holdings (LabCorp), a diagnostics laboratory company with current annual revenue of approximately $10 billion.  Mr. Hayes will chair the Board's audit committee.  With this appointment, Intec's Board has been expanded to eight directors, including seven who are independent. "We are especially pleased to have Brad join the Intec Board of Directors.

  • PR Newswire6 months ago

    Intec Pharma to Present at Jefferies 2018 Healthcare Conference

    Intec Pharma Ltd. (NASDAQ:NETC) (NTEC) ("Intec" or "the Company") today announces that Company management will participate at the upcoming Jefferies 2018 Healthcare Conference taking place June 5 - 8, 2018 in New York City. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website, where it will also be archived for a period of time. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.

  • PR Newswire7 months ago

    Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update

    More than 350 patients enrolled in pivotal Phase 3 ACCORDANCE trial and more than 80% of eligible patients entered the open label extension study JERUSALEM , May 15, 2018 /PRNewswire/ -- Intec Pharma Ltd. ...

  • ACCESSWIRE7 months ago

    Blog Exposure - Intec Pharma Shares Phase-1 PK and Safety Data from Accordion Pill Carbidopa/Levodopa at AAN Annual Meeting

    LONDON, UK / ACCESSWIRE / April 26, 2018 / Active-Investors.com has just released a free research report on Intec Pharma Ltd (NASDAQ: NTEC). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NTEC as the Company's latest news hit the wire. On April 24, 2018, the Company, which is a clinical-stage biopharmaceutical organization focused on developing drugs based on its proprietary Accordion Pill platform technology, declared that it presented data from two Phase-1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease at the American Academy of Neurology 2018 Annual Meeting (AAN 2018), in Los Angeles.

  • PR Newswire8 months ago

    Intec Pharma Presented Phase 1 PK and Safety Data From Accordion Pill Carbidopa/Levodopa at American Academy of Neurology Annual Meeting

    Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces that data collected from two Phase 1 studies of its proprietary Accordion Pill Carbidopa/Levodopa (AP-CD/LD) for Parkinson's disease were highlighted in a poster presentation at the American Academy of Neurology 2018 Annual Meeting (AAN 2018) underway in Los Angeles. The poster titled, "Optimizing Delivery of Carbidopa/Levodopa via the Accordion Pill: Comparative PK and Safety From 2 Randomized Crossover Studies in Healthy Volunteers," was delivered by R. Michael Gendreau, M.D., Ph.D. Chief Medical Officer of Intec Pharma, last evening at AAN.

  • PR Newswire8 months ago

    Intec Pharma Announces Closing of $35.4 Million Public Offering of Ordinary Shares

    Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the closing of its previously announced offering of 6.75 million of its ordinary shares, at a public offering price of $5.25 per ordinary share, for gross proceeds of approximately $35.4 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Intec Pharma intends to use the net proceeds from this offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes.

  • PR Newswire8 months ago

    Intec Pharma Announces Pricing of $35.4 Million Public Offering of Ordinary Shares

    JERUSALEM, April 11, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ and TASE: NTEC) today announced the pricing of an underwritten public offering of 6.75 million of its ordinary shares at a public offering price of $5.25 per ordinary share. Intec Pharma has granted the underwriters a 30-day option to purchase up to approximately 1.0 million additional ordinary shares to cover over-allotments. Intec Pharma intends to use the net proceeds from the offering to fund its Phase III clinical trial for Accordion Pill Carbidopa/Levodopa, the company's leading product candidate for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, to advance its pre-commercial activities and for working capital and other general corporate purposes.

  • PR Newswire8 months ago

    Intec Pharma Announces Proposed Public Offering of Ordinary Shares

    JERUSALEM, April 10, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) (NTEC) today announced the launch of an underwritten public offering of its ordinary shares. In connection with this offering, Intec Pharma also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares being offered to cover over-allotments. All ordinary shares in the offering are being offered by Intec Pharma.

  • PR Newswire8 months ago

    Intec Pharma Announces Poster Presentation at American Academy of Neurology Annual Meeting

    JERUSALEM, April 4, 2018 /PRNewswire/ -- Intec Pharma LTD (NTEC) (NTEC) ("Intec" or "the Company") today announces that data collected from the Company's Phase 2 development program of its proprietary Accordion Pill™ oral drug delivery system have been accepted for poster presentation at the American Academy of Neurology 2018 Annual Meeting (AAN 2018) taking place April 21 – 27, 2018 in Los Angeles.

  • PR Newswire8 months ago

    Intec Pharma Ltd. to Host Key Opinion Leader Luncheon on Novel Drug Delivery Solutions in the Treatment of Parkinson's Disease

    The event will feature presentations by KOLs C. Warren Olanow, MD, Mount Sinai School of Medicine, and Karl Kieburtz, MD, MPH, University of Rochester, who will discuss the current treatment landscape and unmet medical need for treating patients with Parkinson's Disease. Intec Pharma's lead product candidate, the Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, is in Phase 3 clinical trials for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

  • PR Newswire9 months ago

    Intec Pharma Appoints Roger J. Pomerantz, M.D. to Board of Directors

    Intec Pharma LTD (NASDAQ, TASE: NTEC) ("Intec" or "the Company") today announces the appointment of Roger J. Pomerantz, M.D., F.A.C.P. to its Board of Directors. Dr. Pomerantz is President, Chief Executive Officer and Chairman of the Board of Directors of Seres Therapeutics, Inc. With this appointment, Intec's board has seven directors including six whom are independent. Prior to joining Seres, Dr. Pomerantz was Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals, and academic alliances.

  • PR Newswire9 months ago

    Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease

    Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces that it has partnered with LTS Lohmann Therapie-Systeme AG ("LTS") for the manufacture of the Company's lead product candidate, Accordion Pill™ Carbidopa/Levodopa (AP-CD/LD) as a treatment for the severe symptoms in advanced Parkinson's Disease patients. Under the agreement, LTS will manufacture the AP-CD/LD capsules using Intec's proprietary Accordion Pill production technology in LTS' manufacturing facility in Andernach, Germany upon the completion of assembly of the production line.